C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer

Biochemical and Biophysical Research Communications

Volumn 450, Issue 1, 2014, Pages 267-273

  Zang, Fenglin ^a   Wei, Xiyin ^a   Leng, Xue ^a   Yu, Man ^b   Sun, Baocun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Apoptosis; C FLIP(L); HER2 positive breast cancer; TRAIL resistance

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLICE INHIBITORY PROTEIN; FLICE INHIBITORY PROTEIN L; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER TISSUE; CONCENTRATION RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR INVASION;

APOPTOSIS; C-FLIP(L); HER2-POSITIVE BREAST CANCER; TRAIL RESISTANCE;

APOPTOSIS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, ERBB-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 84904736127     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.05.106     Document Type: Article

References (28)

1. T. Sorlie, R. Tibshirani, and J. Paker et al. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. U.S.A. 9 2003 8418 8423
2. S.E. Jones, R. Collea, and D. Paul et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study Lancet Oncol. 14 2013 1121 1128
3. O. Micheau, S. Shirley, and F. Dufour Death receptors as targets in cancer Br. J. Pharmacol. 169 2013 1723 1744
4. D.R. Camidge, R.S. Herbst, and M.S. Gordon et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies Clin. Cancer Res. 16 2010 1256 1263
5. M. Rahman, S.R. Davis, and J.G. Pumphrey et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype Breast Cancer Res. Treat. 113 2009 217 230
6. M. Rahman, J.G. Pumphrey, and S. Lipkowitz The TRAIL to targeted therapy of breast cancer Adv. Cancer Res. 103 2009 43 73
7. S. Fulda Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer Expert Opin. Ther. Targets 17 2013 195 201
8. K. Schleich, U. Warnken, and N. Fricker et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model Mol. Cell 47 2012 306 319
9. A. Koenig, I.A. Buskiewicz, and K.A. Fortner et al. The c-FLIPL cleavage product p43FLIP promotes activation of extracellular signal-regulated kinase (ERK), nuclear factor κB (NF-κB), and caspase-8 and T cell survival J. Biol. Chem. 289 2014 1183 1191
10. S.R. Jeffrey, A.S. Elzbieta, and W. Fraser Symmans et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
11. S.M. Tolaney, and I.E. Krop Mechanisms of trastuzumab resistance in breast cancer Anticancer Agents Med. Chem. 9 2009 348 355
12. M. MacFarlane, S.L. Kohlhaas, and M.J. Sutcliffe et al. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies Cancer Res. 65 2005 11265 11270
13. X. Zhang, J. Zhao, and W. Zhu et al. Synergistic effect of subtoxic-dose cisplatin and TRAIL to mediate apoptosis by down-regulating decoy receptor 2 and up-regulating caspase-8, caspase-9 and Bax expression on NCI-H460 and A549 Cells Iran. J. Basic Med. Sci. 16 2013 710 718
14. R.N. Crowder, and W.S. El-Deiry Caspase-8 regulation of TRAIL-mediated cell death Exp. Oncol. 34 2012 160 164
15. S.A. Quast, A. Berger, M. Plötz, and J. Eberle Sensitization of melanoma cells for TRAIL-induced apoptosis by activation of mitochondrial pathways via Bax Eur. J. Cell Biol. 93 2014 42 48
16. N.A. Yacoub, L.F. Fecker, and M. Mobs et al. Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling J. Invest. Dermatol. 132 2012 2263 2274
17. F. Tian, J.J. Lu, and L. Wang et al. Expression of c-FLIP in malignant melanoma, and its relationship with the clinicopathological features of the disease Clin. Exp. Dermatol. 37 2012 259 265
18. I.S. Houdt, J.J. Muris, and A.T. Hesselink et al. Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation Histopathology 51 2007 778 784
19. V. Serra, M. Scaltriti, and L. Prudkin et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Oncogene 30 2011 2547 2557
20. M. Block, C. Gründker, and S. Fister et al. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells Int. J. Oncol. 41 2012 1845 1854
21. L. Piggott, N. Omidvar, and S.M. Perez et al. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL Breast Cancer Res. 13 2011 R88
22. L J. Cell Biol. 190 2010 377 389
23. T. Kataoka, and J. Tschopp N-terminal fragment of c-FLIP(L) processed by caspase 8 specially interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway Mol. Cell Biol. 24 2004 2627 2636
24. A. Golks, D. Brenner, and P.H. Krammer et al. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation J. Exp. Med. 203 2006 1295 1305
25. R. Zielinski, I. Lyakhov, and M. Hassan et al. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors Clin. Cancer Res. 17 2011 5071 5081
26. X. Li, Y. Zhao, and Y. Zhang et al. Tumor necrosis factor a stimulates Her-2 cleavage by activated caspase-8 Cell. Physiol. Biochem. 30 2012 889 897
27. M.R. Abedini, E.J. Muller, and R. Bergeron et al. Akt promotes chemoresistance in human by modulating -induced, p53-dependent ubiquitination of FLICE-like inhibitory protein Oncogene 29 2010 11 25
28. L.E. Perez, N. Parquet, and M. Meads et al. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma Eur. J. Haematol. 84 2010 212 222